<DOC>
	<DOCNO>NCT02632110</DOCNO>
	<brief_summary>The purpose study determine viability microneedle lesion preparation ( MN ) enhance treatment benefit perform prior ALA PDT actinic keratosis ( AK ) field face .</brief_summary>
	<brief_title>Microneedle Lesion Preparation Prior ALA-PDT AK Face</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Four eight AKs face Pregnancy history cutaneous photosensitization , porphyria , hypersensitivity porphyrin photodermatosis lesion suspicious skin cancer ( skin cancer rule biopsy ) untreated skin cancer within Treatment Area skin pathology condition could interfere evaluation test product require use interfere topical systemic therapy Subject immunosuppressed currently enrol investigational drug device study receive investigational drug treat investigational device within 30 day prior initiation treatment know sensitivity one vehicle component ( ethyl alcohol , isopropyl alcohol , laureth 4 , polyethylene glycol ) active herpes simplex infection OR history 2 outbreak within past 12 month , face use follow topical preparation extremity treat : Keratolytics include urea ( great 5 % ) , alpha hydroxyacids [ e.g.glycolic acid , lactic acid , etc . great 5 % ] , salicylic acid ( great 2 % ) within 2 day Curettage Cryotherapy within 2 week initiation treatment Retinoids , include tazarotene , adapalene , tretinoin , within 4 week Microdermabrasion , laser ablative treatment , ALAPDT , chemical peel , 5FU , diclofenac , ingenol mebutate , imiquimod topical treatment AK within 8 week use systemic retinoid therapy within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Actinic Keratosis</keyword>
</DOC>